ALXP
ALGEN
Market cap29mUSD
Oct 28, Last price
2.10EUR
1D
-1.87%
1Q
-13.93%
Jan 2017
17.32%
IPO
-65.06%
Name
Genoway SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
genOway S.A. is a global biotechnology enterprise that specializes in the creation, production, commercialization, and distribution of custom genetically engineered mouse, rat, and cell line models. The company develops bespoke mouse models, including knockout (KO) and knock-in (KI) types, along with customized rat models featuring constitutive and conditional KO, point mutation KI, and rapid KI options. They also engineer custom cell lines, offering constitutive KO, point mutation KI, reporter KI, quick KI, and general KI functionalities. In addition to these tailored solutions, genOway provides a comprehensive catalog of established models, such as humanized immune checkpoint mouse models, immunodeficient and reconstituted mouse and rat strains, humanized immune target models, various other pre-designed mouse and rat models, and immune checkpoint catalog cell lines. Serving a diverse range of clients, including pharmaceutical and life science companies as well as academic research institutions, genOway was founded in 1999 and is headquartered in Lyon, France.
Key people
Christian Grenier
Chairman of the Board · since 2014
Alexandre Fraichard
Chief Executive Officer · since 2014
Benjamin Bruneau
Financial and Administrative Director · since 2017
Director - Representative of Dassaut Developpement · since 2011
Laurent Fraisse
Director
Michel G. Lurquin
Director · since 2001
Denis Soubeyran
Director · since 2015
Andre Tartar
Director · since 2017
Headquarters & legal address
31 RUE SAINT JEAN DE DIEU
TECHNOPARK
LYON 69007
FR
TECHNOPARK
LYON 69007
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |